PROPEL™ (mometasone furoate) sinus implant

The PROPEL™ sinus implant maintains patency and locally delivers steroid to the sinus mucosa in patients 18 years and older following sinus surgery.

Category Sinus Implant

Application Post-Surgical

Manufacturer Medtronic

Request Quote Download Brochure

Description

Enhance your sinus action plan

The PROPEL™ family of sinus implants is the first and only FDA (Food & Drug Administration) approved steroid eluting sinus implant.1 PROPEL™ sinus implants come in three sizes, allowing ENT (Ear, Nose & Throat) physicians to select the best option that conforms to the anatomical needs of their patients.2–4

PROPEL™ sinus implant for the ethmoid sinus2
PROPEL™ Mini sinus implant for ethmoid sinus and frontal sinus opening3
PROPEL™ Contour sinus implant for sinus ostia, frontal and maxillary4

Features

PROPEL™ sinus implants keep the sinuses open while releasing mometasone furoate (MF)

PROPEL™ sinus implants feature an innovative two-in-one mechanism that opens in the sinuses while delivering MF, a potent corticosteroid, directly where it is needed.^2–4

Key Benefits

Self-expanding design that opens and supports the sinus cavity
Delivers 370 mcg of MF over 30 days†
Non-obstructive design allows for sinus mucociliary clearance and the delivery of topical rinses
MF present in the sinus mucosal tissue for up to 60 days⁵
Structural backbone bio-absorbs over approximately 30–45 days after placement as the sinus cavity heals

Mometasone furoate

Mometasone furoate delivers a combination of potency and safety.

Drug characteristics comparison^6–9

Topical corticosteroid	Lipophilicity^‡,6	Potency (receptor affinity)^†,7	Systemic bioavailability^‡,8
Dexamethasone	Very low (<1.0)	Very low (100)	High (76%)
Triamcinolone (Kenalog)	Low (1.0)	Low (233)	Medium (46%)
Budesonide	Low (1.6)	Intermediate (935)	Medium (34%)
Mometasone furoate	High (20.0)	High (2,300)	Very low (<1%)

Optimal sinonasal drug characteristics⁷

Highly lipophilic Readily absorbs into tissue

Targeted and potent High glucocorticoid receptor affinity

Low systemic bioavailability Minimize systemic effects

PROPEL™ sinus implants are clinically proven to maintain patency and improve patient outcomes following endoscopic sinus surgery by targeting inflammation, the underlying cause of chronic rhinosinusitis.